Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06391879
Status:
RECRUITING
Last Update Posted:
2024-04-30
First Post:
2024-04-25
Brief Title:
Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
Sponsor:
Peking University First Hospital
Organization:
Peking University First Hospital
Study Overview
Official Title:
Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma Based on Accurate Genotyping a Population-based Study
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
VHL syndrome is a rare hereditary tumor syndrome caused by mutation of tumor suppressor gene VHL One of the most important clinical manifestations and main cause of death is VHL-related renal cell carcinoma RCC Facing the challenges of multilesion of both kidneys slow progress and life-long repeated surgeries in VHL-related RCC individualized prediction of the best surgical treatment time and reduction of times of surgeries are very important to improve the prognosis of patients with VHL syndrome Therefore there is an urgent need to establish a more effective and accurate prediction model for the natural course of VHL syndrome This cohort-study aims to retrospectively and prospectively analyze the factors related to the natural course of VHL-related RCC At the same time some patients were selected for prospectively continuous molecular evolution dynamic monitoring after comprehensively considering the results of single cell sequencing whole genome and metabonomic sequencing This study will provide scientific basis for accurate diagnosis and treatment of natural course of VHL-related RCC
Detailed Description:
VHL syndrome is a rare hereditary tumor syndrome caused by mutation of tumor suppressor gene VHL One of the most important clinical manifestations and main cause of death is VHL-related renal cell carcinoma RCC Previous small sample studies have confirmed that the natural course of VHL-related RCC is different from that of sporadic RCC Facing the challenges of multilesion of both kidneys slow progress and life-long repeated surgeries in VHL-related RCC individualized prediction of the best surgical treatment time and reduction of times of surgeries are very important to improve the prognosis of patients with VHL-related RCC Therefore there is an urgent need to establish a more effective and accurate prediction model for the natural course of VHL syndrome Based on the previous establishment of the largest biobank of VHL syndrome in Asia as well as the unique characteristics and genotype-phenotypic relationship of patients in Chinese population this cohort-study aims to retrospectively and prospectively analyze the factors related to the natural course of VHL-related RCC At the same time some patients were selected for prospectively continuous molecular evolution dynamic monitoring after comprehensively considering the results of single cell sequencing whole genome and metabonomic sequencing This study will systematically analyze the specific molecular characteristic and evolution of VHL-related different from sporadic RCC reveal new specific driving genes and their molecular regulatory mechanisms and establish a multi-dimensional prediction model of natural course of VHL-related RCC based on accurate genotyping It will provide scientific basis for accurate diagnosis and treatment of natural course of VHL-related RCC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None